MedPath

Hypofractionated Radiotherapy for Lung Cancer

Phase 1
Completed
Conditions
Lung Cancer
Registration Number
NCT00214123
Lead Sponsor
University of Wisconsin, Madison
Brief Summary

The purpose of this trial is to pilot reducing the duration of radiation treatment for lung cancer patients from 6 to 5 weeks using tomotherapy. Specific patient doses will be based on tumor volume being treated. Modeling has shown that increased biologically effective dose (BED) to tumors can be achieved by shortening the radiation delivery schedule and increasing the dose per fraction. This requires decreasing the total dose to hold lung toxicity constant at each dose per fraction level. This is a major paradigm shift in the treatment in this disease and is projected to result in significant improvements in patient outcome as well as a substantial cost savings.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
79
Inclusion Criteria
  • Thoracic neoplasm requiring at lest 60 Gy conventional radiotherapy
Exclusion Criteria
  • Prior bleomycin or gemcitabine chemotherapy
  • Prior thoracic radiotherapy

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Grade 3 pneumonitis lasting greater than 2 weeks90 days post radiotherapy (XRT)
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

University of Wisconsin Hospital and Clinics

🇺🇸

Madison, Wisconsin, United States

University of Wisconsin Hospital and Clinics
🇺🇸Madison, Wisconsin, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.